The key durability question patients actually ask

'Will I need this again in a year?' is the question most patients are really asking when they compare injectable cartilage treatments. The honest answer depends on separating two things that often get conflated: how long the injected material stays in the joint, and how long the patient continues to feel better.

With ChondroFiller, the collagen scaffold is biodegradable and breaks down over roughly 6–24 months — but the clinical benefit it enables can persist for 1–5 years or longer, because the scaffold's job is to support the body's own repair process, not to act as a permanent filler. Arthrosamid, by contrast, is non-biodegradable and integrates into the joint tissue indefinitely. Hyaluronic acid is absorbed within 4–6 months and typically requires repeat dosing to sustain any effect.

Those figures sound comparable until you realise the three treatments address different structures and different problems within the same joint. Duration comparisons only make sense once that distinction is clear.

ChondroFiller scaffold lifespan and how long the benefit lasts

The collagen gel delivered under ultrasound guidance sets within approximately 3–5 minutes of placement, forming a physical template inside the cartilage defect. Its purpose is to recruit the patient's own progenitor cells — a process known as acellular matrix-induced chondrogenesis — rather than to permanently fill space. A 2025 ex vivo model confirmed this happens quickly: DNA content within the scaffold more than doubled by day 14, demonstrating that cell migration begins almost immediately after the outpatient procedure.

The durability story is therefore about what the body builds during the scaffold's lifespan. Published MOCART scores — a standardised MRI measure of how well repair tissue fills, integrates with, and matches surrounding cartilage — sit in the 70–87 range for suitable ChondroFiller patients, a band clinicians generally consider to reflect meaningful tissue coverage rather than a partially empty defect. On the IKDC questionnaire, which rates everyday knee function on a 0–100 scale, patients typically improve by around 30 points — a shift large enough that most report a noticeable difference in walking, managing stairs, and returning to low-impact activity.

A 2024 knee study in 17 patients (mean age 31) found those functional gains plateaued between six and twelve months, suggesting the regenerative window consolidates within the first year post-injection. The longest published follow-up comes from a hip cohort (Mazek, 2021, n=26): 17 of 21 evaluable patients had good or excellent results at three, four, and five consecutive annual reviews. The patient numbers remain modest, and the evidence base does not yet match the decades of follow-up available for surgical alternatives such as osteochondral grafting — but what data exist point consistently in the same direction.

Arthrosamid: permanent integration and what the evidence covers

Arthrosamid (iPAAG) is a hydrogel comprising 97.5% water and 2.5% polyacrylamide. Unlike any of the other injectables in this comparison, it is non-biodegradable: once delivered into the joint, it integrates into the synovial membrane rather than being reabsorbed, providing a lasting mechanical cushion within the joint lining.

A 2022 systematic review of 463 patients confirmed statistically significant efficacy at 52 weeks and 2 years, with Arthrosamid performing numerically better than hyaluronic acid in a head-to-head RCT at those timepoints. Clinicians sometimes cite benefits of up to five years, and the non-biodegradable chemistry makes that plausible in principle — but the robustly published follow-up sits at two years. Patients should treat the five-year figure as a reasonable expectation rather than a finding that has been formally confirmed in the literature.

Because the hydrogel needs time to stabilise within the synovial tissue, relative joint rest is recommended for the first 14 days after the injection; initial soreness and swelling during that window are expected and typically settle. It is worth noting that some of the published studies captured post-injection reactions using the patient-reported term 'sensation of distension' rather than objectively assessed effusion — a methodological difference that may mean the true rate of clinically detectable inflammation is modestly higher than headline figures suggest.

One structural distinction matters throughout: Arthrosamid cushions the synovial lining and is not a cartilage regeneration therapy. That is why it and ChondroFiller — which targets the cartilage surface directly — address different intra-articular problems and can, in suitable patients, be used together in a single appointment.

Hyaluronic acid: the shortest-acting option and what it can realistically do

Sitting at the other end of the durability spectrum, hyaluronic acid (HA) works by a different mechanism entirely: it supplements the joint's natural synovial fluid, improving lubrication and providing some cushioning. That is viscosupplementation — symptom management, not cartilage repair or structural restoration.

The practical implication is straightforward. HA is biodegradable and typically absorbed within around four to six months, making it the shortest-acting option of the three. Any benefit requires repeat injections to sustain, which adds ongoing cost and clinic visits for patients who respond well.

Its appropriate niche is mild-to-moderate osteoarthritis where joint lubrication is the primary unmet need. It is not indicated for the focal, full-thickness cartilage defects — Outerbridge grade III–IV — that an injectable collagen scaffold such as ChondroFiller addresses. Guideline bodies do not agree on its value: OARSI offers conditional support for viscosupplementation, whilst AAOS and ACR take a more sceptical position, reflecting the inconsistency found across trials. If patients have encountered conflicting opinions about HA, that reflects genuine clinical debate rather than misinformation.

Molecular weight varies across preparations — from lower-weight options to cross-linked high-molecular-weight formulations such as Synvisc — and some evidence suggests the latter may sustain effect slightly longer, though robust comparative data are limited.

Why the three treatments are not interchangeable — and when they can combine

Given what the previous sections have established about each treatment's mechanism, one practical implication follows directly: a patient can receive both ChondroFiller and Arthrosamid in a single outpatient appointment. Because the two act on anatomically distinct structures — ChondroFiller as a regenerative scaffold at the cartilage surface, Arthrosamid as a mechanical hydrogel within the synovial lining — they do not compete or cancel each other out. A patient presenting with a focal Outerbridge grade III–IV defect alongside broader OA-related joint deterioration may benefit from both in a complementary rather than overlapping way.

When this combination is under discussion, the mechanism distinction matters. ChondroFiller is the regenerative component, recruiting the patient's own progenitor cells to support repair of the cartilage lesion. Arthrosamid provides the cushioning role, working through the synovial membrane. Neither replaces the other; collapsing both into a generic 'filler' category misrepresents what each one does.

Hyaluronic acid does not share this combination logic in the same way: as a temporary viscosupplement absorbed within roughly four to six months, it occupies a different clinical niche — symptom management in mild-to-moderate OA — rather than a complementary structural role alongside a regenerative scaffold.

Suitability for combination therapy depends on clinical assessment and individual joint status; a specialist consultation is the appropriate place to determine whether one, two, or none of these injections fits a particular patient's presentation.

What to ask a specialist and how to find one

Three questions are worth raising at any initial assessment: whether the cartilage damage is focal or widespread; what Outerbridge grade the imaging suggests; and whether a regenerative scaffold, a mechanical hydrogel, both, or neither fits the clinical picture.

For ChondroFiller specifically, ask about weight-bearing restrictions in the early post-injection period — protected loading matters while cell ingress and early matrix formation take place. For Arthrosamid, it is worth understanding the clinic's follow-up protocol and how post-injection adverse effects are recorded, since published studies have varied in how effusion is captured.

Specialist selection matters: ultrasound-guided placement of an injectable collagen scaffold requires both imaging capability and specific procedural experience. A GP referral is a reasonable starting point, and professional body registers — such as those of the British Orthopaedic Association or the Faculty of Sport and Exercise Medicine — can help identify clinicians with the relevant training. Search MSK also lists specialists across the UK who offer ChondroFiller and other injectable cartilage therapies, searchable by region and specialty.